General principles of medical therapy of inflammatory bowel disease

Gastroenterology Clinics of North America

Volumn 33, Issue 2, 2004, Pages 191-208

  Friedman, Sonia ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BETAMETHASONE SODIUM PHOSPHATE; BUDESONIDE; CALCIUM; CHOLESTEROL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; EUDRAGIT; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MAGNESIUM; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; VITAMIN D;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ANOREXIA; ARTHRALGIA; BONE DENSITY; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CLINICAL PRACTICE; CLINICAL TRIAL; COLON RESECTION; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; ENTERITIS; FATIGUE; FEVER; FLUID RETENTION; GINGIVA HYPERPLASIA; GLOSSITIS; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MENTAL INSTABILITY; MULTIPLE SCLEROSIS; MYCOSIS; MYOPATHY; NAUSEA; OPPORTUNISTIC INFECTION; OSTEOLYSIS; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERICARDITIS; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REMISSION; REVIEW; SEIZURE; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CYCLOSPORINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; QUALITY OF LIFE;

EID: 2942615252     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.02.003     Document Type: Review

References (96)

1. Irvine E.J. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol. 92:1997;18S-24S
2. Jowett S.L., Seal C.J., Barton J.R., Welfare M.R. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 96:2001;2921-2928
3. Cohen R.D. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 16:2002;1603-1609
4. Thirlby R.C., Land J.C., Fenster L.F., Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg. 133:1998;826-832
5. Boonen A., Dagnelie P.C., Feleus A., Hesselink M.A., Muris J.W., Stockbrügger R.W., et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm Bowel Dis. 8:2002;382-389
6. Trachter A.B., Rogers A.I., Leiblum S.R. Inflammatory bowel disease in women: impact on relationship and sexual health. Inflamm Bowel Dis. 8:2002;413-421
7. Sachar D.B. Indications for surgery in inflammatory bowel disease: a gastroenterologist's opinion. Kirsner J.B. Inflammatory bowel disease. 5th edition:2000;611-615 WB Saunders, Philadelphia
8. Sachar D.B. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 9:2003;205-209
9. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ. 4947:1955;1041
10. Powell-Tuck J., Bown R.L., Lennard Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 13:1978;833
11. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 317:1987;1625-1629
12. Hanauer S.B. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 17:2003;131-137
13. Hanauer S.B. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 1:2001;169-176
14. Sutherland L., Roth D., Beck P., May G., Makiyama K. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev. 2:2000;CD000544.5
15. Sutherland L., Roth D., Beck P., May G., Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev. 2:2000;CD000543
16. Hanauer S.B. Review articles: drug therapy; inflammatory bowel disease. N Engl J Med. 334:1996;841-848
17. Stein R.B., Hanauer S.B. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 23:2000;429-448
18. Cohen R.D., Stein R.B., Hanauer S.B. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 94:1999;1587-1592
19. Fernandez-Banares F., Bertran X., Esteve-Comas M., Cabre E., Menacho M., Humbert P., et al. Azathioprine is useful in maintaining remission long-term remission induced by intravenous cyclosporin in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 91:1996;2498-2499
20. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 121:2001;255-260
21. Seidman E.G. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 3:(Suppl 1):2003;S30-S38
22. Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 92:1997;1867-1871
23. d'Albasio G., Pacini F., Camarri E., Messori A., Trallori G., Bonanomi A.G., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 92:1997;1143-1147
24. Banerjee S., Peppercorn M.A. Inflammatory bowel disease: medical therapy of specific clinical presentations. Gastroenterol Clin North Am. 31:2002;185-202
25. Farup P.G., Hovde O., Halvorsen F.A., Raknerud N., Brodin Y. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis: a comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 30:(2):1995;164-170
26. Lemann M., Galian A., Rutgeerts P., Van Heuverzwijn R., Cortot A., Viteau J.M., et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 9:1995;557-562
27. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Predictors of non-compliance with mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 96:2001;2929-2932
28. Kane S., Huo D., Kalyani M. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 1:2003;170-173
29. Kane S., Huo D., Aikens J., Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 114:2003;39-43
30. Baron J.H., Connell A.M., Kanaglunis T.G., Lennard-Jones J.E., Jones F.A. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. BMJ. 2:1962;441-443
31. Jani N., Regueiro M.D. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am. 31:2002;147-166
32. Plevy S.E. Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol. 97:2002;1607-1617
33. Vakil N., Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology. 96:1989;62-67
34. Desramé J., Sabaté J.M., Agher R., Bremont C., Gaudric M., Couturier D., et al. Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol. 97:2002;1785-1791
35. Danielsson A., Hellers G., Lyrenas E., Lofberg R., Nilsson A., Olsson O., et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol. 22:1987;987-992
36. Lofberg R., Ostergaard Thomsen O., Langholz E., Schioler R., Danielsson Suhr O., Graffner H., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 8:1994;623-629
37. Luman W., Gray R.S., Pendek R., Palmer K.R. Prednisolone metasulphobenzoate form retention enemas suppress the hypothalamo-pituitary- adrenal axis. Aliment Pharmacol Ther. 8:1994;255-258
38. Lee D.A., Taylor G.M., James V.H., Walker G. Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21- phosphate as a retention enema. Gut. 20:1979;349-355
39. Kornbluth A., Marion J.F., Sakomon P., Janowitz H.D. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol. 20:1995;280-284
40. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 330:1994;1841-1845
41. Actis G.C., Ottobrelli A., Pera A., Barletti C., Ponti V., Pinna-Pintor M., et al. Continuously infused cyclosporin at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high dose steroids. J Clin Gastroenterol. 17:1993;10-13
42. Actis G.C. Cyclosporin for steroid-refractory ulcerative colitis. Am J Gastroenterol. 95:2000;830
43. Actis G.C., Aimo G., Priolo G., Moscato D., Rizzetto M., Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe, steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis. 4:1998;276-279
44. D'Haens G., Lemmens L., Geboes K., Vanderoputte L., Van Acker F., Mortelmans L., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 120:2001;1323-1329
45. Rowe F.A., Walker J.H., Karp L.C., Vasiliauskas E.A., Plevy S., Targan S.R. Factors predictive of response to cyclosporin treatment for severe steroid-resistant ulcerative colitis. Am J Gastroenterol. 95:2000;2000-2008
46. George J., Present D.H., Pou R., Bodian C., Rubin P.H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 91:1996;1711-1714
47. Ardizzone S., Molteni P., Imbesi V., Bollani S., Bianchi Porro G., Molteni F. Azathioprine in steroio-resistant and steroio-dependant ulcer-active colitis. J Clin Gastroenterol. 25:1997;330-333
48. Best W.R., Becktel J.M., Singleston J.W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 77:1979;843-846
49. Groupe D'Etudes Thérapeutiques Des Affections Inflammatoires Du Tube Digestif (GETAID) presented by Mary JY and Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut. 30:1989;983-989
50. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 122:2002;512-530
51. Harvey R.F., Bradshaw J.M. A simple clinical index of Crohn's disease activity. Lancet. 1:1980;514
52. Irvine E.J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. Mc Master IBD Study Group. J Clin Gastroenterol. 20:1995;27-32
53. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 340:1999;1398-1405
54. Hanauer S.B., Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 96:2001;635-643
55. Summers R.W., Switz D.M., Sessions J.T., Becktel J.M., Best W.R., Kern F., et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology. 77:1979;847-869
56. Singleton J.W., Hanauer S.B., Gitnick G.L., Peppercorn M.A., Robinson M.G., Wruble L.D., et al. Mesalamine capsules of the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 104:1993;1293-1301
57. Colombel J.F., Lémann M., Cassagnou M., Bouhnik Y., Duclos B., Dupas J.L., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes therapeutiques des affections inflammatoires digestives. [GETAID] Am J Gastroenterol. 94:(3):1999;674-678
58. Ursing B., Thor A., Bárány F., Bergelin I., Ganrot-Norlin K., Hoevels J., et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden result. Gastroenterology. 83:1982;550-562
59. Feagan B.G., Sandborn W.J. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev Gastroenterol Disord. 2:2002;S9-S15
60. Thomsen O.Q., Cortot A., Jewell D., Wright J.P., Winter T., Veloso M.V., et al. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Am J Gastroenterol. 97:2002;649-653
61. Prantera C., Cottone M., Pallone F., Annese V., Franze A., Cerutti R., et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 116:1999;521-526
62. Harrison J., Hanauer S.B. Medical treatment of Crohn's disease. Gastroenterol Clin North Am. 31:2002;167-184
63. Camma C., Giunta M., Rosselli M., Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 113:1997;1465-1473
64. Modigliani R., Colombel J.F., Dupas J.L., Dapoigny M., Costil V., Veyrac M., et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology. 110:1996;688-693
65. Messori A., Brignola C., Trallori G., Rampazzo R., Bardazzi G., Belloli C., et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol. 89:1994;692-698
66. Sutherland L., Singleton J., Sessions J., Hanauer S., Krawitt E., Rankin G., et al. Double-blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 32:1991;1071-1075
67. Prantera C., Zannoni F., Scribano M.L., Berto E., Andreoli A., Kohn A., et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 91:1996;328-332
68. Hanauer S.B., Present D.H. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 3:2003;81-92
69. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 86:1984;249-266
70. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 35:1994;360-362
71. Edsbäcker S., Bengtsson B., Larsson P., Lundini P., Nilsson A., Ulmius J., et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 17:2003;525-536
72. Kane S.V., Schoenfeld P., Sandborn W.J., Tremaine W., Hofer T., Feagan B.G. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 16:2002;1509-1517
73. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 123:1995;132-142
74. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut. 37:1995;674-678
75. Kim P.S., Zlatanic J., Korelitz B.I., Gleim G.W. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol. 94:1999;3254-3257
76. Bouhnik Y., Lémann M., Mary J.Y., Scemama G., Taï R., Matuchansky C., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 347:1996;215-219
77. Korelitz B.I., Hanauer S.B., Rutgeerts P., et al. Postoperative prophylaxis with 6-MP, 5-AZA or placebo in Crohn's disease. Gastroenterology. 114:1998;A1011
78. Korelitz B.I., Adler D.J., Mendelsohn R.A., Sacknoff A.L. Long-term efficacy of 6-mercaptopurine in the treatment of Crohn's Disease. Am J Gastroenterol. 88:1993;1198-1205
79. Schröder O., Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 98:2003;530-537
80. Alfadhli A.A., McDonald J.W., Feagan B.G. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2003;CD003459
81. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 332:1995;292-297
82. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 342:2000;1627-1632
83. Chong R.Y., Hanauer S.B., Cohen R.D. The efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 15:2001;35-44
84. Lemann M., Zenjari T., Bouhnik Y., Cosnes J., Mesnard B., Rambaud J.C., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 95:2000;1730-1734
85. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 337:1997;1029-1035
86. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Safety and efficacy of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 117:1999;761-769
87. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT 1 Study Group. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet. 359:2002;1541-1549
88. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 13:2003;601-608
89. Farrell R.J., Alsahli M., Jeen Y.T.G., Falchuck K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 124:2003;917-924
90. Sandborn W.J. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 124:2003;917-922
91. Lim W.S., Powell R.J., Johnston I.D. Tuberculosis and treatment with infliximab. N Engl J Med. 346:2002;623-626
92. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory bowel disease. Arthritis Rheum. 44:2001;2862-2869
93. Janowitz H.D., Bodian C. The placebo response and the "natural history" of inflammatory bowel disease. Inflamm Bowel Dis. 7:2001;61-66
94. Ilnyckyj A., Shanahan F., Anton P.A., Cheang M., Bernstein C.N. Quantification of the placebo response in ulcerative colitis. Gastroenterology. 112:1997;1854-1858
95. Meyers S., Janowitz H.D. The "natural history" of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol. 11:1989;33-37
96. Meyers S., Janowitz H.D. "Natural history" of Crohn's disease: an analytic review of the placebo lesson. Gastroenterology. 87:1984;1189-1192